- Home
- LEO vs LRMR Comparison
LEO vs LRMR Comparison
Compare LEO & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEO
- LRMR
- Stock Information
- Founded
- LEO 1987
- LRMR N/A
- Country
- LEO United States
- LRMR United States
- Employees
- LEO N/A
- LRMR N/A
- Industry
- LEO Trusts Except Educational Religious and Charitable
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- LEO Finance
- LRMR Health Care
- Exchange
- LEO Nasdaq
- LRMR Nasdaq
- Market Cap
- LEO 391.2M
- LRMR 426.9M
- IPO Year
- LEO N/A
- LRMR N/A
- Fundamental
- Price
- LEO $6.28
- LRMR $3.19
- Analyst Decision
- LEO
- LRMR Strong Buy
- Analyst Count
- LEO 0
- LRMR 9
- Target Price
- LEO N/A
- LRMR $19.44
- AVG Volume (30 Days)
- LEO 200.2K
- LRMR 639.4K
- Earning Date
- LEO 01-01-0001
- LRMR 03-13-2025
- Dividend Yield
- LEO 4.01%
- LRMR N/A
- EPS Growth
- LEO N/A
- LRMR N/A
- EPS
- LEO 0.04
- LRMR N/A
- Revenue
- LEO N/A
- LRMR N/A
- Revenue This Year
- LEO N/A
- LRMR N/A
- Revenue Next Year
- LEO N/A
- LRMR N/A
- P/E Ratio
- LEO $152.00
- LRMR N/A
- Revenue Growth
- LEO N/A
- LRMR N/A
- 52 Week Low
- LEO $4.98
- LRMR $3.01
- 52 Week High
- LEO $6.50
- LRMR $12.91
- Technical
- Relative Strength Index (RSI)
- LEO 60.14
- LRMR 37.56
- Support Level
- LEO $6.11
- LRMR $3.06
- Resistance Level
- LEO $6.33
- LRMR $3.52
- Average True Range (ATR)
- LEO 0.05
- LRMR 0.22
- MACD
- LEO 0.01
- LRMR 0.02
- Stochastic Oscillator
- LEO 78.26
- LRMR 15.66
About LEO BNY Mellon Strategic Municipals Inc.
BNY Mellon Strategic Municipals, Inc. is a diversified closed-end management investment company. The fund's investment objective is to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital. Its products are Equity and Fixed Income Mutual Funds, Retail Money Market Funds, Government/Treasury Money Market Funds, Institutional Money Market Funds, and others. BNY Mellon and its affiliates, including BNYM Investment Adviser, INA and others involved in the management, sales, investment activities, business operations or distribution of the Fund, are engaged in businesses and have interests other than that of managing the Fund.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.